Evidence map›Paper›PMID 42741738›Full record

ArticleHemaSphere2026

The machine-learning classifier ALLCatchR2 identifies 20 T-ALL subtypes across cohorts and age groups.

Thomas Beder, Nadine Wolgast, Wencke Walter, Sonja Bendig, Alina M Hartmann, Malwine J Barz, Marketa Zaliova, Elisa-Sophie Reitzel, David Baden, Stefan Schwartz and 8 more

Abstract read
In one paragraph

Article in HemaSphere, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Thomas BederMedical Department II, Hematology and Oncology University Hospital Schleswig-Holstein Kiel Germany.
Nadine WolgastMedical Department II, Hematology and Oncology University Hospital Schleswig-Holstein Kiel Germany.
Wencke WalterMLL Munich Leukemia Laboratory Munich Germany.ORCID https://orcid.org/0000-0002-5083-9838
Sonja BendigMedical Department II, Hematology and Oncology University Hospital Schleswig-Holstein Kiel Germany.ORCID https://orcid.org/0009-0003-0644-9140
Alina M HartmannMedical Department II, Hematology and Oncology University Hospital Schleswig-Holstein Kiel Germany.ORCID https://orcid.org/0009-0002-0638-0000
Malwine J BarzMedical Department II, Hematology and Oncology University Hospital Schleswig-Holstein Kiel Germany.
Marketa ZaliovaChildhood Leukaemia Investigation Prague, Second Faculty of Medicine Charles University and University Hospital Motol Prague Czech Republic.ORCID https://orcid.org/0000-0002-1639-7124
Elisa-Sophie ReitzelMedical Department II, Hematology and Oncology University Hospital Schleswig-Holstein Kiel Germany.
David BadenMedical Department II, Hematology and Oncology University Hospital Schleswig-Holstein Kiel Germany.ORCID https://orcid.org/0000-0002-4519-1002
Stefan SchwartzDepartment of Hematology, Oncology and Cancer Immunology (Campus Benjamin Franklin) Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität and Humboldt-Universität zu Berlin Berlin Germany.
Nicola GökbugetDepartment of Medicine II, Hematology/Oncology Goethe University Frankfurt, University Hospital Frankfurt Germany.
Lennart KesterPrincess Maxima Center for Pediatric Oncology Utrecht The Netherlands.
Jan TrkaChildhood Leukaemia Investigation Prague, Second Faculty of Medicine Charles University and University Hospital Motol Prague Czech Republic.
Claudia HaferlachMLL Munich Leukemia Laboratory Munich Germany.
Monika BrüggemannMedical Department II, Hematology and Oncology University Hospital Schleswig-Holstein Kiel Germany.
Claudia D BaldusMedical Department II, Hematology and Oncology University Hospital Schleswig-Holstein Kiel Germany.
Martin NeumannMedical Department II, Hematology and Oncology University Hospital Schleswig-Holstein Kiel Germany.
Lorenz BastianMedical Department II, Hematology and Oncology University Hospital Schleswig-Holstein Kiel Germany.ORCID https://orcid.org/0000-0002-1487-9437

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

T-cell acute lymphoblastic leukemia (T-ALL) comprises molecularly diverse subtypes, but robust cross-cohort validations and operational gene-expression definitions are lacking. To establish a gene-expression-anchored framework for T-ALL subtyping, we aggregated 2314 transcriptomes (15 cohorts, age: 0.8-90.8 years). An extended unsupervised approach defined 17 main clusters and 3 subclusters in samples with high blast fractions. Supervised analyses added an overarching immature T-ALL (early T cell precursor [ETP]-like) definition and resolved the LMO2 γδ-like subtype. All clusters contained samples from at least two cohorts. Characteristic genomic driver enrichments were consistent across cohorts, while gene-expression clusters did not correspond exclusively to single driver events but also reflected developmental origins. A machine-learning classifier based on ALLCatchR, our B-cell acute lymphoblastic leukemia (B-ALL) classifier, identified these 20 transcriptomic subtypes and the immature T-ALL (ETP-like) signature with 0.995-1.0 accuracy in a validation set (

Identifiers

PMID42741738
PMCPMC13574018

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.